Abstract
Pulmonary hypertension (PH) is a severe and often rapidly progressive disease with fatal outcome. Endothelial dysfunction in PH is associated with decreased nitric oxide production. After reviewing the mechanisms of action and the evidence base for specific therapy with phosphodiesterase 5 inhibitors (PDE-5) and soluble guanylate cyclase stimulators, a reseach review on switching from PDE-5 to riociguat is conducted. A potential advantage of riociguat is its independence from endogenous nitric oxide and from the other (besides PDE-5) isoenzymes of phosphodiesterases. The favorable efficacy profile of sildenafil has been proven for the main forms of pulmonary arterial hypertension, of riociguat for the main forms of pulmonary arterial hypertension and chronic thromboembolic PH. The clinical efficacy of replacing PDE-5 with riociguat has been demonstrated in uncontrolled trials and in the randomized controlled study REPLACE. The possibility of therapy optimization by switching from IFDE-5 to riociguat is fixed in the Russian (class and level of evidence B-3) and Eurasian (class and level of evidence IIb-B) clinical guidelines, as well as in the materials of the Cologne Expert Consensus. An additional argument for switching is the lower cost as compared to combination therapy in the Russian Federation. According to the Russian and Eurasian guidelines for PH and the Russian instructions for the use of riociguat, the drug should be taken at least 24 hours after sildenafil discontinuation.
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice
Reference62 articles.
1. Koshland DE. The Molecule of the Year. Science. 1992;258:1861.
2. Легочная гипертензия. Под ред. И.Е. Чазовой, Т.В. Мартынюк. М.: Практика, 2015; с. 55-103 [Pulmonary hypertension. Ed. IE Chazova, TV Martyniuk. Moscow: Practice, 2015; p. 55-103 (in Russian)].
3. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Российские клинические рекомендации. 2020. Режим доступа: https://cr.minzdrav.gov.ru/recomend/159_1. Ссылка активна на 18.08.2021 [Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian clinical guidelines. 2020. Available at: https://cr.minzdrav.gov.ru/recomend/159_1. Accessed: 18.08.2021 (in Russian)].
4. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (2020)
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献